What We're Reading: Page 118
Industry reads hand-picked by our editors
Nov 22, 2022
-
Reuters
U.S. midterms dampen Big Pharma hopes for drug price policy change
-
The Wall Street Journal
Japan Approves First Homegrown Covid-19 Antiviral Pill
-
C&EN
Birth control for men
Nov 21, 2022
-
Financial Times
Bristol Myers Squibb warns US price reforms will dent drug development
-
Stat News
Biosplice, once the most valuable biotech startup, sees a pair of osteoarthritis trials fail
-
FierceBiotech
Lysogene’s lead gene therapy fails Phase 2/3 trial with cash low
-
CNBC
Theranos founder Elizabeth Holmes sentenced to over 11 years in prison
Nov 18, 2022
-
The New York Times
The End of Covid Vaccines at ‘Warp Speed’
-
Evaluate Vantage
Pulling back the curtain on Astrazeneca’s Car-T work
-
Axios
Get ready for a drug importation revival
Nov 17, 2022
Nov 16, 2022
Nov 15, 2022
-
Wired
The $6 Billion Shot at Making New Antibiotics—Before the Old Ones Fail
-
Bloomberg
Soaring Infant Lung Illnesses Spur Race for Prevention
-
The Wall Street Journal
Walmart to Pay $3.1 Billion to Settle Opioid Lawsuits
-
Kaiser Health News
Thousands of Experts Hired to Aid Public Health Departments Are Losing Their Jobs
Nov 14, 2022
-
Reuters
U.S. seeks 15 years for Elizabeth Holmes over Theranos fraud
-
Bloomberg
Biotech CEO Mark McKenna Explains What Drug Dealmaking Trends to Watch
-
The Financial Times
Bristol Myers Squibb warns UK medicines levy threatens investment
-
Wired
This Personalized Crispr Therapy Is Designed to Attack Tumors
Previous
